Abstract:Universities are increasingly regarded as key actors in the new 'knowledge economy', with requirements to produce market-oriented knowledge and engage in commercialization. This is of particular significance in the biomedical field, reflecting the perceived gap between success in terms of scientific discoveries and its transformation into products. The dominant discourse attributes this situation to 'blocks' in the translational pathway from 'bench to bedside', leading to policies to 'reengineer' the research enterprise. This study examines a pilot initiative established by the UK's Medical Research Council (MRC). This involved employing a change agent (Research Translator) supported by a small amount of translational funding to promote the culture and practice of translational research at a university/hospital site in England. An ethnographically informed case study involving semi-structured and open exploratory interviews, observation and document review, was conducted in 2008. Analysis and interpretation were informed by Bourdieu's logic of practice applied to science. The requirements of translational research promoted by the Research Translator and its sources of capital (authority, prestige etc) were largely congruent with the 'field' of clinical science. In contrast, translational research diverged from perceptions of 'legitimate' science and requirements for capital accumulation held by the majority of basic scientists who often described this research as 'high risk' and were resistant to the Research Translator's advice. However some differences in motivations and practices were identified within groups of scientists associated with career stage, work environment and specialty. We argue that there are convergent and divergent forces that influence scientists' readiness to adopt a market-oriented translational research model and in turn facilitate or constrain the effectiveness of a knowledge broker. We also identify ways in which current structures and policies continue to promote a continuum of forms of knowledge production, thus challenging notions of a linear shift.

From basic research to budding biotechs, under one roof with Stuart Schreiber

How co-working labs reduce costs and accelerate progress for biotech start-ups

The benefits of translating biomedical research at drug discovery institutes

A lab-to-market roadmap for early-stage entrepreneurship

Star-studded AI biotech launch

Careers at Biotech Start-Ups and in Entrepreneurship

Exploring open source as a strategy to enhance R&D productivity

Innovation at the Interface between Academia and Industry: The BioMed X Model

Implementing 'translational' biomedical research: convergence and divergence among clinical and basic scientists

We must discuss research environments

Translational Medicine: Advancing Medical Science by Stimulating Interdisciplinary Research

The innovation menagerie: New institutional structures are expanding horizons for early-stage research

Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles

Promoting 'Academic Entrepreneurship' in Europe and the United States: Creating an Intellectual Property Regime to Facilitate the Efficient Transfer of Knowledge from the Lab to the Patient

Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh-Dole Act

The winding journey of biotech capital raising: deciphering the jargon

A European Salk Institute Could Ensure Accessible and Affordable Medicines

The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model

Create a translational medicine knowledge repository--research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: how will they avoid relearning old lessons?

A Paradox of the Field's Own Success: Unintended Challenges in Bringing Cutting-Edge Science from the Bench to the Market

Translational Medicine is Developing in China: a New Venue for Collaboration.